Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and finished the day at $8.47. Traded volume was 69,618.00million shares in the last session and the average volume of the stock remained 73.64K shares. OvaScience Inc (NASDAQ:OVAS) insider ownership is 24.30%.

BioTime, Inc (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $2.50 per share, with a total value of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) dropped -0.92 percent to $3.23 Thursday on volume of 478,911.00million shares. The intra-day range of the stock was $3.20 to $3.33. BioTime, Inc. (NYSEMKT:BTX) has a market capitalization of $233.04million.

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor acquired 5,000 shares of the stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, with a total value of $127,200.00. Insys Therapeutics Inc (NASDAQ:INSY)’s stock on June 19, 2014 reported a increase of 5.30% to the closing price of $29.80. Its fifty two weeks range is $7.15 -$57.91. The total market capitalization recorded $1.02billion. The overall volume in the last trading session was 804,408.00million shares. In its share capital, INSY has 34.23million outstanding shares.

Novavax, Inc (NASDAQ:NVAX) SVP John Trizzino bought 16,500 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.51 per share, with a total value of $74,415.00. Following the completion of the acquisition, the senior vice president now directly owns 16,500 shares of the company’s stock, valued at approximately $74,415. On Thursday, shares of Novavax, Inc. (NASDAQ:NVAX) advanced 3.10% to close the day at $4.82. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as 9.41%.  Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -2.72%.

ImmuCell Corporation (NASDAQ:ICCC) Director ROTHSCHILD JONATHAN E bought 5,901 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.566 per share, with a total value of $26,945.00. Following the completion of the acquisition, the Director now directly owns shares of the company’s stock, valued at approximately $510,536. ImmuCell Corporation (NASDAQ:ICCC) stock performance was 2.27% in last session and finished the day at $4.51. Traded volume was 199.00million shares in the last session and the average volume of the stock remained 2.59K shares. The beta of the stock remained -0.17. ImmuCell Corporation (NASDAQ:ICCC) insider ownership is 2.20%.